Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

Share Price is delayed by 15 minutes
Get Live Data
2.44    -0.005 (-0.20%)
Bid:
2.43
Ask:
2.445
Spread: 0.015 (0.617%)
Market Cap: $8.05b
CBKD Live PriceLast checked at - London Stock Exchange

Intraday Com.int.bk.regs Share Chart

  • This share is an international stock.

3rd Quarter Results

4 Nov 2025 07:00

RNS Number : 0095G
Commercial Intnl Bank (Egypt) SAE
03 November 2025
 

Condensed Separate Interim Statement of Financial Position as at September 30, 2025

Notes

Sep. 30, 2025

 

Dec. 31, 2024

 

 

 

Assets

 

Cash and balances at the central bank

10

20,916,631

 

136,165,920

Due from banks

11

228,152,325

 

270,089,441

Loans and advances to banks, net

13

26,914,884

 

9,555,410

Loans and advances to customers, net

14

452,110,898

 

340,955,698

Derivative financial instruments

1,222,908

 

819,711

Financial investments

 

 

 

- Financial Assets at Fair Value through P&L

15

2,203,869

 

-

- Financial Assets at Fair Value through OCI

15

329,796,707

 

233,029,903

- Financial Assets at Amortized cost

15

228,915,634

 

167,276,956

Investments in subsidiaries and associates

16

1,255,421

 

871,525

Non-current assets held for sale

30

159,828

 

159,828

Other assets

17

49,915,056

 

44,175,232

Deferred tax assets

2,457,493

 

2,337,304

Property and equipment

18

5,470,642

3,881,620

Total assets

 

1,349,492,296

 

1,209,318,548

 

Liabilities and equity

 

 

 

Liabilities

 

 

 

Due to banks

19

7,043,881

 

2,317,715

Due to customers

20

1,043,204,762

 

967,895,387

Derivative financial instruments

223,670

 

100,571

Current income tax liabilities

15,857,818

 

18,327,968

Other liabilities

21

26,802,780

 

21,347,499

Issued debt instruments

22

4,779,461

 

5,067,781

Other loans

30,249,278

 

23,962,389

Other provisions

23

14,478,190

18,613,060

Total liabilities

 

1,142,639,840

1,057,632,370

 

Equity

 

 

 

Issued and paid capital

30,708,510

 

30,431,580

Reserves

105,209,974

 

63,125,912

Reserve for employee stock ownership plan (ESOP)

2,071,247

 

1,868,235

Retained earnings*

 

68,862,725

56,260,451

Total equity and net profit for the period / year

 

206,852,456

151,686,178

 

Total liabilities and equity

 

1,349,492,296

1,209,318,548

 

The accompanying notes are an integral part of these financial statements.

 

(Review report attached)

 

*

Including net profit for the period

 

 

Condensed Separate Interim Income Statement for the period ended September 30, 2025

 

 

Last 9 Months

 

Last 9 Months

 

Notes

 

Sep. 30, 2025

 

Sep. 30, 2024

 

 

 

 

 

 

 

Interest and similar income

 

157,761,416

 

130,537,149

Interest and similar expense

 

(79,403,286)

(65,010,779)

Net interest income

 

 

78,358,130

65,526,370

 

 

 

 

Fee and commission income

 

11,565,784

 

9,257,495

Fee and commission expense

 

(5,224,939)

(4,048,928)

Net fee and commission income

 

 

6,340,845

5,208,567

 

 

 

 

Dividend income

 

125,185

 

100,858

Net trading income

6

 

1,276,502

 

18,177,630

Profits (Losses) on financial investments 

15.1

 

598,228

 

377,992

Administrative expenses

 

(11,880,346)

 

(8,795,429)

Other operating income (expenses)

7

 

687,384

 

(17,980,232)

Impairment release (charges) for credit losses

9

7,976,997

(3,741,208)

Profit before income tax

 

83,482,925

58,874,548

 

 

 

 

Income tax expense

27

 

(21,867,730)

 

(16,964,163)

Deferred tax assets (Liabilities)

27

 

592,311

646,991

Net profit for the period

 

 

62,207,506

 

42,557,376

 

 

 

Earnings per share

8

 

 

Basic

18.54

 

12.50

Diluted

18.36

 

12.38

 

 

 

 

Condensed Separate Interim Statement of Comprehensive Income for the period ended September 30, 2025

 

 

Last 9 Months

 

Last 9 Months

 

 

Sep. 30, 2025

 

Sep. 30, 2024

 

 

 

 

 

 

 

Net profit for the period

 

 

62,207,506

42,557,376

 

 

 

 

Transferred to RE from financial assets at fair value through OCI

 

3,586

 

(370,224)

Net change on financial assets at fair value through comprehensive income after tax

 

6,805,836

 

8,284,110

Effect of ECL on fair value of debt instruments measured at fair value through comprehensive income

 

 

(399,884)

624,524

Total comprehensive income for the period

 

 

68,617,044

 

51,095,786

 

 

Condensed Separate Interim Cash Flows for the period ended September 30, 2025

 

Notes

Sep. 30, 2025

 

Sep. 30, 2024

 

 

 

Cash flow from operating activities

 

 

Profit before income tax

 

83,482,925

 

58,874,548

Adjustments to reconcile profits to net cash provided by operating activities

 

 

 

Fixed assets depreciation

18

1,244,370

763,079

Impairment release/charge for credit losses (Loans and advances to customers and banks)

9

(7,980,073)

4,226,051

Net charged/released for other provisions

23

(4,080,370)

429,182

Impairment release/charge for credit losses (due from banks)

9

151,236

(5)

Impairment release/charge for credit losses (financial investments)

9

(148,160)

(484,838)

Impairment release/charge for other assets

-

(11,956)

Exchange revaluation differences for financial assets at fair value through OCI and AC

4,669,694

(18,536,183)

Revaluation differences impairment charge for Financial Assets at Fair value through OCI

(225,004)

1,199,896

Revaluation differences impairment charge for Financial Assets at Amortized cost

(16,709)

107,207

Revaluation differences impairment charge for due from banks

(7,813)

107

Net utilized/recovered for other provisions

23

(2,039)

(9,196)

Exchange revaluation differences of other provisions

23

(52,461)

3,963,023

Profits/losses from selling property and equipment

(8,006)

(2,254)

Profits/losses from selling financial investments at fair value through OCI

15.1

(416,668)

(377,992)

Profits/losses from selling investments in associates

15.1

(181,560)

-

Share based payments

 

990,324

 

804,345

Operating profits before changes in operating assets and liabilities

 

77,419,686

 

50,945,014

 

 

 

Net decrease / increase in assets and liabilities

 

 

 

Due from banks

158,353,929

(24,748,544)

Financial assets at fair value through P&L

(2,203,869)

(2,066,889)

Derivative financial instruments

(306,569)

(229,127)

Loans and advances to banks and customers

(120,567,170)

(74,803,105)

Other assets

(2,706,703)

(14,036,648)

Due to banks

19

4,726,166

(8,606,431)

Due to customers

20

75,309,375

221,382,197

Current income tax obligations paid

(6,009,912)

(2,694,657)

Other liabilities

 

(12,872,687)

(6,305,033)

Net cash generated from (used in) operating activities

 

171,142,246

 

138,836,777

 

 

 

Cash flow from investing activities

 

 

 

Proceeds from sale of investments in associates

339,920

11,956

Payments for investment in subsidiaries

(542,256)

(200,000)

Payments for purchases of property, equipment and branches construction

(5,833,944)

(2,284,236)

Proceeds from selling property and equipment

7

8,006

2,254

Proceeds from redemption of financial assets at amortized cost

21,249,023

1,093,724

Payments for purchases of financial assets at amortized cost

(83,115,289)

(105,723,312)

Payments for purchases of financial assets at fair value through OCI

(192,334,673)

(21,646,713)

Proceeds from selling financial assets at fair value through OCI

98,063,752

67,015,091

Net cash generated from (used in) investing activities

 

(162,165,461)

(61,731,236)

 

Condensed Separate Interim Cash Flows for the period ended September 30, 2025 (Cont.)

 

Sep. 30, 2025

 

Sep. 30, 2024

 

 

 

Cash flow from financing activities

 

 

 

Other loans

6,286,889

7,840,786

Dividends

(14,714,434)

(5,078,792)

Issued debt instruments

(288,320)

1,738,393

Capital increase

276,930

236,570

Net cash generated from (used in) financing activities

(8,438,935)

4,736,957

 

 

 

Net (decrease) increase in cash and cash equivalent during the period

537,850

81,842,498

Beginning balance of cash and cash equivalent

227,028,744

233,912,193

Cash and cash equivalent at the end of the period

 

227,566,594

 

315,754,691

 

 

 

Cash and cash equivalent comprise:

 

 

 

Cash and balances at the central bank

10

20,916,631

 

94,285,689

Due from banks

228,295,965

 

304,041,410

Treasury bills and other governmental notes

12

140,546,840

82,174,775

Obligatory reserve balance with CBE

(2,725,245)

 

(76,128,521)

Due from banks with maturity more than three months

(19,202,757)

(17,846,556)

Treasury bills and other governmental notes with maturity more than three months

 

(140,264,840)

(70,772,106)

Total cash and cash equivalent

 

227,566,594

 

315,754,691

 

 

Condensed Separate Interim statement of changes in shareholders' equity

 

Issued and paid capital

Legal reserve

General reserve

General risk reserve

Special reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Sep. 30, 2024

 

Beginning Balance at 1 January 2024

30,195,010

4,770,354

39,840,707

1,549,445

-

21,155

(16,808,265)

15,230

29,230,360

1,486,010

90,300,006

Capital increase

236,570

-

-

-

-

-

-

-

-

-

236,570

Transferred to reserves

-

1,438,320

22,582,085

-

-

1,663

-

-

(23,398,943)

(623,125)

-

Dividend paid

-

-

-

-

-

-

-

-

(5,366,429)

-

(5,366,429)

Net profit for the period

-

-

-

-

-

-

-

-

42,557,376

-

42,557,376

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

-

(370,224)

-

370,224

-

-

Net change on financial assets at fair value through OCI after tax

-

-

-

-

-

-

8,284,110

-

-

-

8,284,110

Transferred (from) to banking risk reserve

-

-

-

-

-

-

-

2,694

(2,694)

-

-

Effect of ECL on debt instruments measured at fair value through OCI

-

-

-

-

-

-

624,524

-

-

-

624,524

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

804,345

804,345

 Balance at 30 September 2024

30,431,580

6,208,674

62,422,792

1,549,445

-

22,818

(8,269,855)

17,924

43,389,894

1,667,230

137,440,502

 

 

Issued and paid capital

Legal reserve

General reserve

General risk reserve

Special reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Sep. 30, 2025

 

 

 

 

 

 

 

 

 

 

 

Beginning Balance at 1 January 2025

30,431,580

6,208,674

62,422,792

1,549,445

-

22,818

(7,095,741)

17,924

56,260,451

1,868,235

151,686,178

Capital increase

276,930

-

-

-

-

-

-

-

-

-

276,930

Transferred to reserves

-

2,771,284

19,758,610

-

-

2,246

-

-

(21,744,828)

(787,312)

-

Dividends paid

-

-

-

-

-

-

-

-

(14,714,434)

-

(14,714,434)

Net profit for the period

-

-

-

-

-

-

-

-

62,207,506

-

62,207,506

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

-

3,586

-

(3,586)

-

-

Transferred from net profit to special reserve

-

-

-

-

13,145,012

-

-

-

(13,145,012)

-

-

Net change on financial assets at fair value through OCI after tax

-

-

-

-

-

-

6,805,836

-

-

-

6,805,836

Transferred (from) to banking risk reserve

-

-

-

-

-

-

-

(2,628)

2,628

-

-

Effect of ECL on debt instruments measured at fair value through OCI

-

-

-

-

-

-

(399,884)

-

-

-

(399,884)

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

990,324

990,324

 Balance at 30 September 2025

30,708,510

8,979,958

82,181,402

1,549,445

13,145,012

25,064

(686,203)

15,296

68,862,725

2,071,247

206,852,456

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTUPGGWGUPAGBW
Date   Source Headline
12th May 202610:18 amRNS1st Quarter Results
12th May 202610:16 amRNSCIB Consolidated Financial Statements 1Q26
12th May 202610:15 amRNS1Q26 Earnings Release
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
24th Feb 202612:31 pmRNSItems of Extraordinary GA
24th Feb 20267:00 amRNSPress Release dated 23th February 2026
19th Feb 20261:20 pmRNSItems of Extraordinary GA
19th Feb 20261:17 pmRNSInvitation to the Extraordinary GA 2026
19th Feb 20268:00 amRNSItems of OGA 2026
19th Feb 20268:00 amRNSInvitation to the OGA March 15
10th Feb 20267:00 amRNSCIB Summary of Board Resolution 9 Feb 2026
10th Feb 20267:00 amRNSFY25 Earnings Release
10th Feb 20267:00 amRNSCIB IFRS Consolidated Financial Statements FY25
15th Dec 20257:00 amRNSChange in Board of Directors
3rd Dec 20254:35 pmRNSCIB Bonus Shares Distribution 2025
4th Nov 20257:00 amRNSCIB Condensed Consolidated 3rd Quarter Results
4th Nov 20257:00 amRNSCIB 9M25 Earnings Release
4th Nov 20257:00 amRNS3rd Quarter Results
25th Sep 20253:55 pmRNSSummary of Resolutions - GAM September 2025
1st Sep 20257:02 amRNSInvitation to General Assembly September 2025
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Consolidated Financials
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Separate Financials
22nd Jul 20257:00 amRNS2Q25 Earnings Release
28th May 20256:00 pmRNSChanges to the Board of Directors
13th May 20257:00 amRNSSeparate- Q12025
13th May 20257:00 amRNS1Q25 Press Release
13th May 20257:00 amRNSConsolidated Financial Position at March 31.2025
24th Mar 20257:00 amRNSOrdinary General Assembly Resolutions Summary 2025
28th Feb 20257:00 amRNSGeneral Assembly 2025 - Discussion Items - amended
27th Feb 20257:47 amRNSInvitation to General Assembly 2025
27th Feb 20257:15 amRNSGeneral Assembly 2025 - Discussion Items
19th Feb 20257:00 amRNSCIB Annual Financial Report
19th Feb 20257:00 amRNSCIB FY2024 Earnings Release
6th Nov 20247:58 amRNSCIB gets regulatory approvals to changes to BoD
4th Nov 20247:00 amRNSEarnings Release 3Q.2024
4th Nov 20247:00 amRNSCIB-Separate Financial Statements 3Q.2024
4th Nov 20247:00 amRNSCIB-Consolidated Financial Statements 3Q.2024
1st Oct 20242:00 pmRNSCIB obtaining Long term loan from IFC
16th Sep 20248:00 amRNSChanges in CIB's Board of Directors
22nd Jul 20247:00 amRNSCIB H1-2024 Separate Financial Statements - E
22nd Jul 20247:00 amRNSH1.2024 Press Release
22nd Jul 20247:00 amRNSCIB H1-2024 Consolidated Financial Statements
13th May 20247:00 amRNS1st Quarter Results - Separate Statements
13th May 20247:00 amRNS1st Quarter Results - Consolidated Statements
26th Mar 20247:49 amRNSChanges in CIB's BOD - 25 March 2024
26th Mar 20247:00 amRNSOGM Resolutions - March 25th, 2024
26th Mar 20247:00 amRNSEGM Resolutions - March 25th, 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.